Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:321 (11 February), doi:10.1136/bmj.332.7537.321
Jeanne Lenzer
New York
| The first 150 words of the full text of this article appear below. |
An inhaled form of human insulin, Exubera, has been approved in Europe and the United States for the treatment of type 1 and 2 diabetes in adults. The drug, to be marketed jointly by Pfizer and Sanofi-Aventis, was hailed by the US Food and Drug Administration as the "first new insulin delivery option introduced since the discovery of insulin in the 1920s."
Both the FDA and the European Agency for the Evaluation of Medicinal Products have specified that the drug, which will not be available for several months, is contraindicated in smokers and in patients who have smoked in the preceding six months. It is "not recommended" in patients with asthma, bronchitis, or emphysema.
The European agency has also specified that Exubera is indicated only for "adult patients with type 2 diabetes mellitus not adequately controlled with oral antidiabetic agents and requiring insulin therapy" or for patients with type 1
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses